High shear mixing of lactose and salmeterol xinafoate dry powder blends: Biopharmaceutic and aerodynamic performances

[1]  B. Forbes,et al.  Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers. , 2015, International journal of pharmaceutics.

[2]  P. Colombo,et al.  "Pierce and inhale" design in capsule based dry powder inhalers: Effect of capsule piercing and motion on aerodynamic performance of drugs. , 2015, International journal of pharmaceutics.

[3]  H. Chrystyn,et al.  NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma , 2014, Expert opinion on drug delivery.

[4]  P. Royall,et al.  Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers. , 2014, International journal of pharmaceutics.

[5]  A. Hickey.  Back to the future: inhaled drug products. , 2013, Journal of pharmaceutical sciences.

[6]  N. Scichilone,et al.  Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations , 2013, Journal of asthma and allergy.

[7]  R. H. Bridson,et al.  Exploring the effects of high shear blending on lactose and drug using fluidised bed elutriation. , 2012, International journal of pharmaceutics.

[8]  P. Colombo,et al.  Particles and powders: tools of innovation for non-invasive drug administration. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[9]  J. Willetts.  Investigation into the effects of high shear blending and storage on powders for inhalation , 2012 .

[10]  A H de Boer,et al.  A critical view on lactose-based drug formulation and device studies for dry powder inhalation: which are relevant and what interactions to expect? , 2012, Advanced drug delivery reviews.

[11]  K. Amighi,et al.  Lactose characteristics and the generation of the aerosol. , 2012, Advanced drug delivery reviews.

[12]  D. Morton,et al.  Drug-lactose binding aspects in adhesive mixtures: controlling performance in dry powder inhaler formulations by altering lactose carrier surfaces. , 2012, Advanced drug delivery reviews.

[13]  S. Jones,et al.  Critical characteristics for corticosteroid solution metered dose inhaler bioequivalence. , 2012, Molecular pharmaceutics.

[14]  A. Hickey,et al.  Pulmonary formulations: what remains to be done? , 2010, Journal of aerosol medicine and pulmonary drug delivery.

[15]  Jonathan Seville,et al.  The effects of high shear blending on α-lactose monohydrate , 2007 .

[16]  I. Krämer,et al.  Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers. , 2006, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[17]  W. Finlay,et al.  Predicting extrathoracic deposition from dry powder inhalers , 2004 .

[18]  Rebecca Lynn Johnson,et al.  Towards the bioequivalence of pressurised metered dose inhalers 1: design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.